portal
  Home About us Reports Charts News Custom Company Scan  
Report Charts News
*
Title Content
Economy&Goods
  Economy
  ConsumerGoods
  Food&Beverage
  Agriculture
Life Sciences
  Biotechnology
  Medical
  Pharmaceutical
Manufacturing
  Automotive
  Chemical
  Energy
  Machinery
  Material
  Metals & Minerals
Public Sector
  Environment
  Finance Service
  Infrastructure
  Logistics
  Real Estate
  Retailing
  Tourism
  Training
Technology And Media
  Electronics
  Internet
  Hardware
  Media
  Software
  Telecommunications

Tel: 0086-10-82600828
Fax: 0086-10-82601570
Email:


 Dendreon to cut 150 jobs as cancer vaccine sales drop again
 
CreateTime:2013-11-13 Editor:liaoyan
Text Size:       
 

 Biotechnology company Dendreon Corp said it would reduce annual costs by $125 million and cut about 150 jobs in a new round of restructuring, as it struggles to boost sales of its flagship cancer vaccine.

Dendreon's net product revenue, reflecting Provenge sales, fell 13 percent to $68 million in the third quarter ended September 30.

Dendreon had cut 600 jobs and closed its New Jersey manufacturing facility in a restructuring in July last year to save about $150 million annually.

Dendreon said it would have about 820 employees at the end of the restructuring, down from more than 2,000 at its peak.


Related Reports
China Animal Vaccine Industry Report, 2019-2025
China Blood Product Industry Report, 2020-2026
China Vacuum Blood Collection Device Industry Report, 2019-2025
China Human Vaccine Industry Report, 2019-2025
China Independent Clinical Laboratory Industry Report, 2019-2025
2005-2021 www.researchinchina.com All Rights Reserved 京ICP备05069564号-1